LUNG CANCER
Scope & Guideline
Pioneering Insights in Oncology and Pulmonary Medicine
Introduction
Aims and Scopes
- Focus on Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC):
The journal predominantly explores both NSCLC and SCLC, covering various aspects including diagnosis, treatment modalities, and patient outcomes. - Emphasis on Immunotherapy and Targeted Therapy:
Significant research is dedicated to immunotherapeutic approaches, particularly immune checkpoint inhibitors, and targeted therapies focusing on specific mutations like EGFR, MET, and ALK. - Clinical Trials and Real-World Studies:
The journal publishes findings from clinical trials as well as real-world studies that provide insights into treatment effectiveness and patient management strategies. - Molecular and Genomic Characterization:
Research on the molecular and genomic landscape of lung cancer, including genetic mutations and their implications for treatment, is a core area of focus. - Patient-Centered Outcomes and Quality of Life:
The journal also emphasizes studies that assess patient-reported outcomes, preferences, and quality of life, recognizing the importance of patient-centered approaches in lung cancer care.
Trending and Emerging
- Integration of AI and Machine Learning:
There is a growing trend towards utilizing artificial intelligence and machine learning for predictive modeling in lung cancer, enhancing diagnostic accuracy and treatment planning. - Focus on Combination Therapies:
Research increasingly examines the efficacy of combination therapies that integrate immunotherapy with chemotherapy or targeted therapies, aiming for synergistic effects in treatment outcomes. - Personalized Medicine and Biomarker Research:
A significant emphasis is placed on personalized medicine, particularly studies focusing on biomarkers that guide treatment decisions and predict patient responses to therapies. - Longitudinal and Follow-Up Studies:
There is an emerging trend in conducting longitudinal studies to evaluate long-term outcomes and the impact of treatment strategies over time, enhancing understanding of survivorship. - Management of Comorbidities in Lung Cancer Patients:
Research is increasingly addressing the management of comorbidities in lung cancer patients, recognizing the complex interplay between cancer treatment and overall health.
Declining or Waning
- Traditional Chemotherapy Protocols:
Research related to standard chemotherapy protocols appears to be declining as newer targeted therapies and immunotherapies take precedence in treatment discussions. - Surgical Techniques Without Adjuvant Therapy:
There is a noticeable reduction in studies focusing solely on traditional surgical techniques without the integration of adjuvant therapies, reflecting a shift towards more comprehensive treatment approaches. - Epidemiological Studies on Smoking:
While smoking remains a significant risk factor for lung cancer, studies specifically focusing on smoking epidemiology are less frequent, as the focus shifts to molecular and genetic factors. - Histopathological Classification Alone:
The reliance on histopathological classifications without molecular profiling is waning, as there is an increased emphasis on molecular characterization and personalized medicine.
Similar Journals
Kidney Cancer
Unlocking the future of kidney cancer treatment through open access.Kidney Cancer, published by IOS PRESS, is an esteemed open-access journal dedicated to advancing knowledge in the field of nephrology and oncology. Since its inception in 2017, this journal has provided a dynamic platform for researchers, practitioners, and students to disseminate their findings and discuss innovative approaches to kidney cancer treatment and research. With an ongoing commitment to fostering collaboration and sharing critical insights, Kidney Cancer aims to bridge gaps in understanding and promote new methodologies in patient care. Despite its current ranking in the lower quartiles of its category, the journal is positioned to make significant contributions to the academic community by publishing high-quality, peer-reviewed articles that enhance the discourse in kidney cancer research. Furthermore, its open-access model ensures that valuable research is accessible to a global audience, supporting the urgent need for advancements in this critical area of health. Join the conversation and contribute to the growing body of knowledge in this vital field.
International Journal of Clinical Oncology
Shaping the Future of Cancer ManagementInternational Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.
Thoracic Cancer
Pioneering discoveries in thoracic health.Thoracic Cancer is a distinguished open-access journal published by WILEY, dedicated to advancing the field of thoracic oncology. Since its establishment in 2010, the journal has emerged as a crucial platform for the dissemination of innovative research and clinical studies relating to lung cancer and other thoracic malignancies. With a commendable impact reflected in its 2023 Q2 rankings in the categories of Medicine (Miscellaneous), Oncology, and Pulmonary and Respiratory Medicine, the journal features high-quality articles that are vital for researchers, clinicians, and students aspiring to enhance their understanding of thoracic cancers. Operating out of Australia, Thoracic Cancer has embraced a commitment to open access since 2015, ensuring that vital research is readily available to a global audience. The journal's rigorous peer-review process and emphasis on novel findings make it an indispensable resource for professionals seeking to stay at the forefront of this rapidly evolving field.
SEMINARS IN ONCOLOGY
Championing the Fight Against Cancer with KnowledgeSEMINARS IN ONCOLOGY is a premier journal in the field of oncology, published by W B Saunders Co-Elsevier Inc. With its ISSN 0093-7754 and E-ISSN 1532-8708, this esteemed publication has been contributing significantly to cancer research and education since its inception in 1974. The journal currently holds a distinguished position in the academic landscape, ranking in the Q1 category for Hematology and Q2 for Oncology, and featured prominently in Scopus rankings—34th out of 137 in Medicine Hematology, and 108th out of 404 in Medicine Oncology. SEMINARS IN ONCOLOGY aims to disseminate cutting-edge research, critical reviews, and innovative treatment approaches, making it an invaluable resource for researchers, healthcare professionals, and students dedicated to the fight against cancer. Although not an Open Access journal, it maintains a commitment to high-quality, peer-reviewed content, further solidifying its role as a vital reference point in oncological studies. The journal serves as a crucial platform for the exchange of knowledge, insights, and advancements that shape the future of cancer care.
Cancer Discovery
Catalyzing Collaboration for a Cancer-Free FutureCancer Discovery, published by the American Association for Cancer Research, stands as a vital resource in the oncological research community, renowned for its commitment to disseminating groundbreaking studies and innovative findings in cancer biology, prevention, diagnostics, and treatment. With a significant impact factor reflecting its esteemed position, this journal facilitates open discussions and collaborations, striving to bridge the gap between experimental and clinical research. The journal, which has been active since 2011, is classified as a Q1 publication in 2023, underscoring its influence and authority in the realm of Oncology. By providing a platform for rigorous peer-reviewed articles, Cancer Discovery aims to advance our understanding of cancer and enhance therapeutic strategies, making it an indispensable tool for researchers, professionals, and students eager to stay at the forefront of cancer research.
Oncology Research and Treatment
Elevating cancer research to new heights.Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.
Molecular Therapy Oncolytics
Exploring the Frontiers of Molecular Medicine in OncologyMolecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Navigating the Evolving Landscape of Cancer CareCURRENT TREATMENT OPTIONS IN ONCOLOGY, published by Springer, is a premier academic journal dedicated to disseminating cutting-edge research and advancements in the field of oncology and pharmacology. With a commendable impact factor and ranked in the Q1 category in both oncology and pharmacology for 2023, this journal positions itself as a leading resource for researchers, healthcare professionals, and students alike, offering insightful reviews and original articles that critically evaluate treatment methodologies and clinical practices. Covering a wide scope of topics from early detection to innovative therapies, it fosters the translation of research findings into clinical applications. With its convergence years spanning from 2000 to 2024, CURRENT TREATMENT OPTIONS IN ONCOLOGY continues to be at the forefront of oncological research, providing a platform for scholars to explore the latest therapeutic options and improve patient outcomes. Highly regarded in the academic community, this journal is essential for anyone looking to stay informed about the dynamic landscape of cancer treatment.
International Cancer Conference Journal
Leading the Charge Against Cancer Through KnowledgeInternational Cancer Conference Journal, published by Springer International Publishing AG, serves as a pivotal platform for the dissemination of cutting-edge research in the field of oncology. With a commitment to advancing the understanding, prevention, and treatment of cancer, this journal offers a forum for the presentation of innovative studies, clinical trials, and comprehensive reviews that cater to the needs of researchers, healthcare professionals, and students alike. Although currently not open access, the journal is dedicated to fostering collaboration and knowledge sharing within the cancer research community. The ISSN for this journal is 2192-3183, ensuring its listing within prominent academic databases for enhanced visibility. Hailing from Switzerland, the journal aspires to impact the global dialogue on cancer through rigorous peer-reviewed articles and special conference proceedings, making it an essential resource for those dedicated to the fight against cancer.
Turk Onkoloji Dergisi-Turkish Journal of Oncology
Fostering impactful discoveries in the realm of oncology.Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.